<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03752216</url>
  </required_header>
  <id_info>
    <org_study_id>GINECO-OV239B</org_study_id>
    <secondary_id>2018-002274-44</secondary_id>
    <nct_id>NCT03752216</nct_id>
  </id_info>
  <brief_title>NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.</brief_title>
  <acronym>NiQoLe</acronym>
  <official_title>Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a longitudinal, national, open, multi-centre phase IV study which will recruit up to&#xD;
      141 patients with ovarian cancer in late relapse treated with niraparib according to the&#xD;
      labelling In France.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of NiQoLe, phase IV study is to evaluate tolerability of Niraparib and the management&#xD;
      by the physicians of the side-effects in real life in France. The study will also generate&#xD;
      complementary data of NOVA trial on longitudinal follow up of closed symptoms and side&#xD;
      effects reported by the patients especially with the NCI PRO (Patient-Reported Outcome)-CTCAE&#xD;
      system. Specific oncogeriatric data will be collected among on a subgroup of elderly&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities inducing dose modifications of Niraparib between the start to the cycle 3 (interruption, discontinuation and dose reduction).</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate treatment toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported fatigue by patient by FACT-F questionnaire (Functional Assessment of Cancer Therapy General - Fatigue)</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Functional Assessment of Cancer Therapy General Fatigue questionnaire (score range from 0 to 52 - Higher scores represent better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported symptoms and side effects with the NCI PRO-CTCAE</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Self-reported symptoms and side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons of the dose modification of Niraparib</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Reasons of the dose modification of Niraparib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health-related quality of life by FACT-G questionnaire (Functional Assessment of Cancer Therapy General)</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Functional Assessment of Cancer Therapy General questionnaire (score range from 0 [worse outcome] to 108 [better outcome])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain related to the treatment by Visual Analogic Scale (VAS)</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Score range from 0 [worse outcome] to 10 [better outcome])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of interest (HTA, anemia, thrombocytopenia)</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Side effects of interest (HTA, anemia, thrombocytopenia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Niraparib treatment</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>From the start of Niraparib until progression or unacceptable toxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent line of anti-cancer therapy</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>From the stop of Niraparib to the first subsequent line of anti-cancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 18 months.</time_frame>
    <description>Overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial cognitive functions by FACT-cog (Functional Assessment of Cancer Therapy - Cognitive Function) questionnaire</measure>
    <time_frame>At the inclusion visit</time_frame>
    <description>FACT-cog questionnaire (score range from 0 to 132 - Higher scores represent better functioning)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of Niraparib before Niraparib administration</measure>
    <time_frame>Day 8</time_frame>
    <description>residual dosage of Niraparib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of Niraparib before Niraparib administration</measure>
    <time_frame>3 months</time_frame>
    <description>residual dosage of Niraparib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale (score range from 0 [better outcome] to 30 [worse outcome])</measure>
    <time_frame>Up to 6 months.</time_frame>
    <description>Geriatric Depression Scale (score range from 0 [better outcome] to 30 [worse outcome])</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>NIRAPARIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Niraparib Daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>Two different doses of Niraparib can be administrated:&#xD;
For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.&#xD;
For patient who had at baseline (T0) a body weight &lt; 77 kg or a platelet count &lt;150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.&#xD;
Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria.</description>
    <arm_group_label>NIRAPARIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        I-1 Female patients must be ≥ 18 years of age. I-2 Signed informed consent and ability to&#xD;
        comply with treatment and follow-up. I-3 Patients with histologically proved high grade&#xD;
        epithelial ovarian cancer or fallopian tube or primary peritoneal adenocarcioma.&#xD;
&#xD;
        I-4 Platine sensitive and ovarian, fallopian or peritoneal cancer recurrent patients with a&#xD;
        complete response or partial response after a line of platine based chemotherapy.&#xD;
&#xD;
        I-5 Participant must have adequate organ function, defined as follows:&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/μL&#xD;
&#xD;
          -  Platelets ≥ 100,000/μL&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine&#xD;
             clearance ≥ 30 mL/min using the Cockcroft-Gault equation&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN (≤2.0 in patients with known Gilberts syndrome) OR direct&#xD;
             bilirubin ≤ 1 x ULN&#xD;
&#xD;
          -  Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver&#xD;
             metastases are present, in which case they must be ≤ 5 x ULN I-6 Patients with an&#xD;
             indication of maintenance by Niraparib after platine based chemotherapy according to&#xD;
             the labelling (see appendix 17).&#xD;
&#xD;
        I-7 As this study will include patients in France, a subject will be eligible in this study&#xD;
        only if either affiliated to, or a beneficiary of, a social category.&#xD;
&#xD;
        I-8 Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
        of ≤ 2.&#xD;
&#xD;
        I-9 Participant receiving corticosteroids may continue as long as their dose is stable for&#xD;
        least 4 weeks prior to initiating protocol therapy.&#xD;
&#xD;
        I-10 Participant must agree to not donate blood during the study or for 90 days after the&#xD;
        last dose of Niraparib.&#xD;
&#xD;
        I-11 Female participant has a negative urine or serum pregnancy test within 7 days prior to&#xD;
        taking study treatment if of childbearing potential and agrees to abstain from activities&#xD;
        that could result in pregnancy from screening through 1 month after the last dose of study&#xD;
        treatment, or is of nonchildbearing potential.&#xD;
&#xD;
        I-12 Participant must agree to not breastfeed during the study or for 1 month after the&#xD;
        last dose of Niraparib.&#xD;
&#xD;
        I-13 Participant must have normal blood pressure or adequately treated and controlled&#xD;
        hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        E-1 Known hypersensitivity or allergy to active principle or to any components or&#xD;
        excipients of the Niraparib formulation.&#xD;
&#xD;
        E-2 Participant must not be simultaneously enrolled in any interventional clinical trial.&#xD;
&#xD;
        E-3 Participant must not have had major surgery ≤ 3 weeks prior to initiating protocol&#xD;
        therapy and participant must have recovered from any surgical effects.&#xD;
&#xD;
        E-4 Participant must not have received investigational therapy ≤ 4 weeks, or within a time&#xD;
        interval less than at least 5 half-lives of the investigational agent, whichever is&#xD;
        shorter, prior initiating protocol therapy.&#xD;
&#xD;
        E-5 Participant last treatment with platinum-based chemotherapy was ≥12 weeks from&#xD;
        initiation of protocol therapy E-6 Participant has had radiation therapy encompassing &gt;20%&#xD;
        of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to Day 1 of&#xD;
        protocol therapy.&#xD;
&#xD;
        E-7 Participant must not have received a transfusion (platelets or red blood cells) ≤ 4&#xD;
        weeks NiQoLe - Study protocol - v3.0 on 08/10/2020 Page 10 on 109 N° EudraCT:&#xD;
        2018-002274-44 prior to initiating protocol therapy. E-8 Participant must not have received&#xD;
        colony stimulating factors (e.g., granulocyte colonystimulating factor, granulocyte&#xD;
        macrophage colony stimulating factor, or recombinant erythropoietin) within 4 weeks prior&#xD;
        initiating protocol therapy. E-9 Participant has had any known Grade 3 or 4 anemia,&#xD;
        neutropenia or thrombocytopenia due to prior chemotherapy that persisted &gt; 4 weeks and was&#xD;
        related to the most recent treatment. E-10 Participant must not have any known history of&#xD;
        myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). E-11 Participant must not&#xD;
        have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active,&#xD;
        uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular&#xD;
        arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure&#xD;
        disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric&#xD;
        disorder that prohibits obtaining informed consent. E-12 Participant must not be deprived&#xD;
        of liberty, under guardianship or under trusteeship.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence JOLY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse 3, avenue du Général Harris 14076 CAEN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sainte-Catherine Institut du Cancer Avignon-Provence</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Tivoli</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Fleyriat</name>
      <address>
        <city>Bourg-en-bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medipole de Savoie</name>
      <address>
        <city>Challes-les-Eaux</city>
        <zip>73190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SASU Centre d'Oncologie et Radiothérapie 37</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste de Grenoble - Institut Daniel Hollard</name>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Hôpitaux de Chartres - Hôpital Louis Pasteur</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ORACLE - Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre ONCOGARD - Institut de Cancérologie du Gard</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses-Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre CARIO - HPCA</name>
      <address>
        <city>Plérin</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint-Malo</name>
      <address>
        <city>Saint-Malo</city>
        <zip>35400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>Saint-nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg - Institut de Cancérologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Anti-PARP (poly-ADP ribose polymerase)</keyword>
  <keyword>Late Relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

